Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03058666 |
Recruitment Status :
Completed
First Posted : February 23, 2017
Last Update Posted : March 13, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Respiratory Distress Syndrome | Drug: Aerosolized Calfactant Device: Solarys | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 477 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients |
Actual Study Start Date : | March 29, 2017 |
Actual Primary Completion Date : | June 1, 2018 |
Actual Study Completion Date : | July 31, 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Aerosolized Calfactant
|
Drug: Aerosolized Calfactant
Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
Other Names:
Device: Solarys Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator. |
No Intervention: Usual Care
There will be no protocol driven interventions in the usual care group.
|
- Intubation [ Time Frame: 72 hours ]Incidence of the requirement for endotracheal intubation and instillation of surfactant to "usual care".
- Death [ Time Frame: 28 days ]Incidence of death
- Bronchopulmonary Dysplasia [ Time Frame: 28 days or discharge ]Incidence of Bronchopulmonary Dysplasia defined as oxygen requirement to maintain acceptable blood oxygenation saturations.
- Severity of Acute RDS [ Time Frame: Randomization to 72 hours of age or to intubation ]Measured by oxygen requirements and respiratory support

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 24 Hours (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
RDS Patients
- NICU patient, ≥1hour of age and <24 hours of age.
- Clinical diagnosis of RDS, with or without chest X-ray data.
- Inspired oxygen ≥21% to maintain adequate oxygen saturation.
- Not intubated
-
Requiring:
- nasal continuous positive airway pressure (nCPAP).
Exclusion Criteria:
- Congenital anomaly limiting care options or requiring early surgery.
-
Cardiopulmonary decompensation.
- hypotension with metabolic acidosis (base excess < -10 meq/l).
- Oxygen saturations < 88% at start of aerosolization.
- PaCO2 ≥ 60 mmHg at start of aerosolization.
- Grade 3 or Grade 4 intraventricular hemorrhage by cranial ultrasound, if known.
- Acute hypoxic encephalopathy with or without seizures.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03058666

Study Chair: | James Cummings, MD | Albany Medical College |
Responsible Party: | ONY |
ClinicalTrials.gov Identifier: | NCT03058666 |
Other Study ID Numbers: |
Aero-02 |
First Posted: | February 23, 2017 Key Record Dates |
Last Update Posted: | March 13, 2019 |
Last Verified: | March 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Aerosol surfactant calfactant Infasurf |
Respiratory Distress Syndrome RDS Premature Neonates |
Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Respiration Disorders Respiratory Tract Diseases Lung Diseases |
Infant, Premature, Diseases Infant, Newborn, Diseases Calfactant Pulmonary Surfactants Respiratory System Agents |